HMG-CoA reductase inhibitors and P-glycoprotein modulation

被引:162
作者
Bogman, K
Peyer, AK
Török, M
Küsters, E
Drewe, J
机构
[1] Univ Basel Hosp, Kantonsspital, Dept Clin Pharmacol & Toxicol, CH-4031 Basel, Switzerland
[2] Novartis Pharma AG, Dept Chem & Analyt Dev, Basel, Switzerland
关键词
statins; P-glycoprotein; rhodamine; in vitro; confocal microscopy; drug interactions; HMG-CoA reductase inhibitors;
D O I
10.1038/sj.bjp.0703920
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Five 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), (e.g. atorvastatin, fluvastatin, lovastatin, pravastatin and simvastatin), were investigated for their ability to reverse P-glycoprotein (P-gp) mediated rhodamine 123 (R123) transport in a murine monocytic leukaemia cell line that over-expresses the multi-drug resistance protein 1a/b (mdr1a/1b). 2 P-gp modulation was studied by a fluorimetric assay and confocal microscopy by means of R123 efflux and uptake experiments, respectively. 3 Atorvastatin acid, methyl ester and lactone, lovastatin lactone and simvastatin lactone inhibited R123 transport in a concentration-dependent manner. Lovastatin acid, simvastatin acid, fluvastatin and pravastatin did not show a significant inhibition of the R123 transport in our cell system. Atorvastatin methyl ester and lactone showed the highest affinities for P-gp and results were comparable for both methods. 4 In conclusion, monitoring of R123 transport in living cells by confocal microscopy in addition to fluorimetric assay is a sensitive tool to study P-gp affinity in drug screening that is especially useful for early phases of drug development.
引用
收藏
页码:1183 / 1192
页数:10
相关论文
共 50 条
[1]   Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].
Ambudkar, SV ;
Dey, S ;
Hrycyna, CA ;
Ramachandra, M ;
Pastan, I ;
Gottesman, MM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :361-398
[2]   The interaction of diltiazem with lovastatin and pravastatin [J].
Azie, NE ;
Brater, DC ;
Becker, PA ;
Jones, DR ;
Hall, SD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (04) :369-377
[3]  
BOESCH D, 1991, CANCER RES, V51, P4226
[4]   'Fire and forget?' - pharmacological considerations in coronary care [J].
Bottorff, M .
ATHEROSCLEROSIS, 1999, 147 :S23-S30
[5]   Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion [J].
Boyd, RA ;
Stern, RH ;
Stewart, BH ;
Wu, XC ;
Reyner, EL ;
Zegarac, EA ;
Randinitis, EJ ;
Whitfield, L .
JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (01) :91-98
[6]  
CHENG HY, 1994, DRUG METAB DISPOS, V22, P139
[7]   Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar? [J].
Christians, U ;
Jacobsen, W ;
Floren, LC .
PHARMACOLOGY & THERAPEUTICS, 1998, 80 (01) :1-34
[8]   New insights into the pharmacodynamic and pharmacokinetic properties of statins [J].
Corsini, A ;
Bellosta, S ;
Baetta, R ;
Fumagalli, R ;
Paoletti, R ;
Bernini, F .
PHARMACOLOGY & THERAPEUTICS, 1999, 84 (03) :413-428
[9]   CLINICAL IMPLICATIONS OF THE BIOPHARMACEUTICAL PROPERTIES OF FLUVASTATIN [J].
DESLYPERE, JP .
AMERICAN JOURNAL OF CARDIOLOGY, 1994, 73 (14) :D12-D17
[10]   HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P-glycoprotein-expressing cells [J].
Dimitroulakos, J ;
Yeger, H .
NATURE MEDICINE, 1996, 2 (03) :326-333